title: Plasma glucose, insulin, free fatty acids, lactate and cortisol concentrations in dexmedetomidine-sedated dogs with or without MK-467: a peripheral α-2 adrenoceptor antagonist.
abstract: Six healthy laboratory Beagles were treated IV with 10 μg/kg dexmedetomidine (DEX) or 10 μg/kg dexmedetomidine combined with 500 μg/kg MK-467 in the same syringe (DMK) in a randomised cross-over design with a 14 day washout. Blood was collected immediately before treatment and 35, 60 and 120 min post-injection through a central venous catheter. The plasma concentrations of glucose, insulin, non-esterified free fatty acids (NEFAs), lactate and cortisol were determined. A repeated-measures ANOVA test was used to compare treatments and effects for each sample time point. Significant differences between treatments were found for plasma glucose (P=0.037) and insulin (P=0.009). DEX significantly increased plasma glucose at 120 min, but reduced plasma insulin at 35 and 60 min. NEFA decreased for both treatments at 35 min. This reduction was transient for DMK, whereas it persisted during the follow up period for DEX. Plasma lactate concentrations increased at 35 and 60 min with DEX. Neither treatment altered plasma cortisol concentrations. The addition of MK-467 to dexmedetomidine prevented or abolished most metabolic changes in healthy Beagles.
authors.affiliation: Veterinary Pharmacology and Toxicology, Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Koetilantie 7, PO Box 57, FI-00014 Helsinki, Finland. flavia.restitutti@helsinki.fi
authors.forename: F
authors.initials: F
authors.lastname: Restitutti
authors.forename: M
authors.initials: M
authors.lastname: Raekallio
authors.forename: M
authors.initials: M
authors.lastname: Vainionpää
authors.forename: E
authors.initials: E
authors.lastname: Kuusela
authors.forename: O
authors.initials: O
authors.lastname: Vainio
mesh_terms: D061605:Administration, Intravenous / Q000662:veterinary; D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D058669:Adrenergic alpha-2 Receptor Antagonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000704:Analysis of Variance; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D001774:Blood Chemical Analysis / Q000662:veterinary; D001784:Blood Gas Analysis / Q000662:veterinary; D001786:Blood Glucose / Q000032:analysis; D003124:Colorimetry / Q000662:veterinary; D018592:Cross-Over Studies; D020927:Dexmedetomidine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004285:Dogs; D004338:Drug Combinations; D005260:Female; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood; D008297:Male; D008954:Models, Biological; D011807:Quinolizines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011863:Radioimmunoassay / Q000662:veterinary
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D018686:Anesthetics, Intravenous; D001786:Blood Glucose; D004338:Drug Combinations; D007328:Insulin; D011807:Quinolizines; C055732:vatinoxan; D020927:Dexmedetomidine; D006854:Hydrocortisone